StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.72MP/E –Yield –

CytomX Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

CytomX Therapeutics's price to book ratio was 1.3× on Nov 11, 2026, against 4.7× a year earlier. Over the last 5 years it ranged from 1.3× to 21.3×, with a median of 5.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.3×−3.4
2025Dec 31, 20254.6×−5.2
2022Jan 31, 20229.9×+0.6
2021Dec 31, 20219.3×+3.0
2020Dec 31, 20206.3×+1.7
2019Dec 31, 20194.6×+0.3
2018Dec 31, 20184.3×−12.9
2017Dec 29, 201717.2×+12.7
2016Dec 30, 20164.5×–

More CytomX Therapeutics figures

See a number that looks wrong?